Advertisement

Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases

  • Kazuyo Shimada
  • Shiori Hasegawa
  • Satoshi Nakao
  • Ririka Mukai
  • Kiyoka Matsumoto
  • Mizuki Tanaka
  • Hiroaki Uranishi
  • Mayuko Masuta
  • Shohei Nishida
  • Shinya Shimizu
  • Yuichi Hayashi
  • Akio Suzuki
  • Mitsuhiro NakamuraEmail author
Original Article
  • 22 Downloads

Abstract

Purpose

Ifosfamide is extensively used to treat several malignant conditions. Administration of ifosfamide can cause encephalopathy and other neurotoxic effects. The aim of this study was to obtain novel information on the onset profiles of ifosfamide-induced encephalopathy (IIE) considering other associated clinical factors using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER) databases.

Methods

We analyzed the reports of encephalopathy between 2004 and 2018 from the FAERS and JADER databases. To define IIE, we used the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms and standardized queries. The reporting odds ratios (ROR) at 95% confidence interval (CI) was used to detect the signal for IIE and adjusted for covariates using a multivariate logistic regression technique. We evaluated the time-to-onset profile of IIE and used the association rule mining technique to discover undetected associations, such as potential risk factors.

Results

In the FAERS database, the ROR (CI) for encephalopathy (preferred term, PT) and encephalopathy (standardized MedDRA queries, SMQ) was 56.58 (51.69–61.93) and 1.57 (1.48–1.67), respectively. In the JADER database, the ROR (95% CI) for encephalopathy (PT) and encephalopathy (SMQ) was 13.54 (9.91–18.50) and 1.24 (1.01–1.53), respectively. The multivariate logistic regression analysis showed a significant contribution in IIE signal in the ≥ 60 year group (p = 0.00094; vs. < 60 year group) and ≥ 2000 mg/m2 dosage group (p = 0.00045; vs. < 2000 mg/m2 dosage group). The association rules of {ifosfamide, aprepitant} → {encephalopathy (SMQ)} demonstrated high lift values. The average dose of ifosfamide in patients with encephalopathy (PT) and without encephalopathy (PT) was 2022.8 ± 592.8 (mean ± standard deviation) and 1568.5 ± 703.2 mg/m2, respectively (p < 0.05). Encephalopathy within the first 7 days of ifosfamide administration was 94.1% for encephalopathy (PT) and 87.7% for encephalopathy (SMQ), respectively.

Conclusions

The present analysis demonstrated that the incidence of encephalopathy with ifosfamide should be closely monitored for a short onset (within 7 days). The patients who are administered a high dose of ifosfamide or co-administrated aprepitant should be carefully monitored for the development of encephalopathy.

Keywords

Ifosfamide Encephalopathy FDA Adverse Event Reporting System Japanese Adverse Drug Event Report FAERS JADER 

Notes

Funding

This research was partially supported by the Japan Society for the Promotion of Science KAKENHI (Grant no. 17K08452). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Compliance with ethical standards

Conflict of interest

There are no conflicts of interest to declare.

Ethical approval

Ethical approval was not sought for this study because the study was a database-related observational study without directly involving any research subjects.

References

  1. 1.
    Zalupski M, Baker LH (1988) Ifosfamide. J Natl Cancer Inst 80:556–566CrossRefGoogle Scholar
  2. 2.
    Sioka C, Kyritsis AP (2009) Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 63:761–767.  https://doi.org/10.1007/s00280-008-0876-6 CrossRefGoogle Scholar
  3. 3.
    Visarius TM, Stucki JW, Lauterburg BH (1999) Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats. J Pharmacol Exp Ther 289:820–824Google Scholar
  4. 4.
    David KA, Picus J (2005) Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Oncol 28:277–280CrossRefGoogle Scholar
  5. 5.
    Szabatura AH, Cirrone F, Harris C, McDonnell AM, Feng Y, Voit D, Neuberg D, Butrynski J, Fisher DC (2015) An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. J Oncol Pharm Pract 21:188–193.  https://doi.org/10.1177/1078155214527143 CrossRefGoogle Scholar
  6. 6.
    Lo Y, Shen LJ, Chen WH, Dong YH, Wu FL (2016) Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: a retrospective analysis. J Formos Med Assoc 115:744–751.  https://doi.org/10.1016/j.jfma.2015.07.016 CrossRefGoogle Scholar
  7. 7.
    Stern N, Sakji I, Defachelles AS, Lervat C, Ryckewaert T, Marliot G, Peugniez C, Deplanque D, Penel N (2017) Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients. Bull Cancer 104:208–212.  https://doi.org/10.1016/j.bulcan.2016.11.007 CrossRefGoogle Scholar
  8. 8.
    Baxter Healthcare Corporation. Highlights of prescribing information. IFEX (Ifosfamide) for injection, intravenous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf Accessed 6 Aug 2019
  9. 9.
    Hasegawa S, Matsui T, Hane Y, Abe J, Hatahira H, Motooka Y, Sasaoka S, Fukuda A, Naganuma M, Hirade K, Takahashi Y, Kinosada Y, Nakamura M (2017) Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database. PLoS One 12:e0182045.  https://doi.org/10.1371/journal.pone.0182045 CrossRefGoogle Scholar
  10. 10.
    Naganuma M, Motooka Y, Sasaoka S, Hatahira H, Hasegawa S, Fukuda A, Nakao S, Shimada K, Hirade K, Mori T, Yoshimura T, Kato T, Nakamura M (2018) Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report database. SAGE Open Med 6:1–11.  https://doi.org/10.1177/2050312118772475 CrossRefGoogle Scholar
  11. 11.
    U. S. Food and Drug Administration. “README.DOC” file for the quarterly data extract (QDE) from the FDA adverse event reporting system (FAERS). http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193.htm Accessed 6 Aug 2019
  12. 12.
    Habibzadeh F, Habibzadeh P, Yadollahie M (2016) On determining the most appropriate test cut-off value: the case of tests with continuous results. Biochem Med 26:297–307.  https://doi.org/10.11613/BM.2016.034 CrossRefGoogle Scholar
  13. 13.
    Bate A, Evans SJ (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18:427–436.  https://doi.org/10.1002/pds.1742 CrossRefGoogle Scholar
  14. 14.
    Suzuki Y, Suzuki H, Umetsu R, Uranishi H, Abe J, Nishibata Y, Sekiya Y, Miyamura N, Hara H, Tsuchiya T, Kinosada Y, Nakamura M (2015) Analysis of the interaction between clopidogrel, aspirin and proton pump inhibitors using the FDA Adverse Event Reporting System database. Biol Pharm Bull 38:680–686.  https://doi.org/10.1248/bpb.b14-00191 CrossRefGoogle Scholar
  15. 15.
    Takeyama M, Sai K, Imatoh T, Segawa K, Hirasawa N, Saito Y (2017) Influence of Japanese regulatory action on denosumab-related hypocalcemia using Japanese Adverse Drug Event Report database. Biol Pharm Bull 40:1447–1453.  https://doi.org/10.1248/bpb.b17-00266 CrossRefGoogle Scholar
  16. 16.
    Abe J, Umetsu R, Uranishi H, Suzuki H, Nishibata Y, Kato Y, Ueda N, Sasaoka S, Hatahira H, Motooka Y, Masuta M, Nakamura M (2017) Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database. PLoS One 12:e0190102.  https://doi.org/10.1371/journal.pone.0190102 CrossRefGoogle Scholar
  17. 17.
    Zhu AL, Li J, Leong TY (2003) Automated knowledge extraction for decision model construction: a data mining approach. In: AMIA Annual Symposium Proceedings, pp 758–762Google Scholar
  18. 18.
    Hahsler M, Grün B, Hornik K, Buchta C (2005) A computational environment for mining association rules and frequent item sets. J Stat Softw 14:1–25.  https://doi.org/10.18637/jss.v014.i15 CrossRefGoogle Scholar
  19. 19.
    Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius V (2013) Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf 36:995–1006.  https://doi.org/10.1007/s40264-013-0061-7 CrossRefGoogle Scholar
  20. 20.
    Nakamura M, Umetsu R, Abe J, Matsui T, Ueda N, Kato Y, Sasaoka S, Tahara K, Takeuchi H, Kinosada Y (2015) Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events. J Pharm Health Care Sci 1:34.  https://doi.org/10.1186/s40780-015-0035-2 CrossRefGoogle Scholar
  21. 21.
    Ajithkumar T, Parkinson C, Shamshad F, Murray P (2007) Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol) 19:108–114CrossRefGoogle Scholar
  22. 22.
    ElDesoky ES (2007) Pharmacokinetic–pharmacodynamic crisis in the elderly. Am J Ther 14:488–498CrossRefGoogle Scholar
  23. 23.
    Tajino T, Kikuchi S, Yamada H, Takeda A, Konno S (2010) Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors. J Orthop Sci 15:104–111.  https://doi.org/10.1007/s00776-009-1431-y CrossRefGoogle Scholar
  24. 24.
    Rieger C, Fiegl M, Tischer J, Ostermann H, Schiel X (2004) Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs 15:347–350CrossRefGoogle Scholar
  25. 25.
    Howell JE, Szabatura AH, Hatfield Seung A, Nesbit SA (2008) Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. J Oncol Pharm Pract 14:157–162.  https://doi.org/10.1177/1078155208093930 CrossRefGoogle Scholar
  26. 26.
    Shindorf ML, Manahan KJ, Geisler JP (2013) The interaction of ifosfamide and aprepitant in gynecologic malignancies. Gynecol Oncol Case Rep 12:34–35.  https://doi.org/10.1016/j.gynor.2013.06.002 CrossRefGoogle Scholar
  27. 27.
    Kataria PS, Kendre PP, Patel AA (2017) Ifosfamide-induced encephalopathy precipitated by aprepitant: a rarely manifested side effect of drug interaction. J Pharmacol Pharmacother 8:38–40.  https://doi.org/10.4103/jpp.JPP_182_16 CrossRefGoogle Scholar
  28. 28.
    Lentz KL, Clark SM, Ayarza M, Liu B, Morgan KP, Wind LS, Hairston A (2019) Evaluation of thiamine for the prevention of ifosfamide-induced encephalopathy. J Oncol Pharm Pract.  https://doi.org/10.1177/1078155219859644 Google Scholar
  29. 29.
    Richards A, Marshall H, McQuary A (2011) Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity. J Oncol Pharm Pract 17:372–380.  https://doi.org/10.1177/1078155210385159 CrossRefGoogle Scholar
  30. 30.
    Gharaibeh EZ, Telfah M, Powers BC, Salacz ME (2018) Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy. J Oncol Pharm Pract.  https://doi.org/10.1177/1078155218808361 Google Scholar
  31. 31.
    Bernard PA, McCabe T, Bayliff S, Hayes D Jr (2010) Successful treatment of ifosfamide neurotoxicity with dexmedetomidine. J Oncol Pharm Pract 16:262–265.  https://doi.org/10.1177/1078155209360074 CrossRefGoogle Scholar
  32. 32.
    Kato Y, Umetsu R, Hosoya N, Ueda N, Abe J, Nakayama Y, Motooka Y, Kinosada Y, Oyama M, Nakamura M (2016) Analysis of licorice-induced pseudoaldosteronism in the Japanese Adverse Drug Event Report database. Tradit Kampo Med 3:63–70.  https://doi.org/10.1002/tkm2.1029 CrossRefGoogle Scholar
  33. 33.
    Poluzzi E, Raschi E, Piccinni C, Ponti FD (2012) Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). Intech, Rijeka, pp 265–302Google Scholar
  34. 34.
    Hartnell NR, Wilson JP (2004) Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 24:743–749CrossRefGoogle Scholar
  35. 35.
    McAdams MA, Governale LA, Swartz L (2008) Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect. Pharmacoepidemiol Drug Saf 17:882–889.  https://doi.org/10.1002/pds.1633 CrossRefGoogle Scholar
  36. 36.
    Nomura K, Takahashi K, Hinomura Y, Kawaguchi G, Matsushita Y, Marui H, Anzai T, Hashiguchi M, Mochizuki M (2015) Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases. Drug Des Dev Ther 9:3031–3041.  https://doi.org/10.2147/DDDT.S81998 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Kazuyo Shimada
    • 1
  • Shiori Hasegawa
    • 1
    • 4
  • Satoshi Nakao
    • 1
  • Ririka Mukai
    • 1
  • Kiyoka Matsumoto
    • 1
  • Mizuki Tanaka
    • 1
  • Hiroaki Uranishi
    • 1
    • 5
  • Mayuko Masuta
    • 1
    • 6
  • Shohei Nishida
    • 2
  • Shinya Shimizu
    • 2
  • Yuichi Hayashi
    • 3
  • Akio Suzuki
    • 2
  • Mitsuhiro Nakamura
    • 1
    Email author
  1. 1.Laboratory of Drug InformaticsGifu Pharmaceutical UniversityGifuJapan
  2. 2.Department of PharmacyGifu University HospitalGifuJapan
  3. 3.Department of NeurologyGifu University Graduate School of MedicineGifuJapan
  4. 4.Department of PharmacyKobe City Medical Center General HospitalKobe-cityJapan
  5. 5.Division of PharmacyNara Medical University HospitalNaraJapan
  6. 6.Division of PharmacyKyoto City HospitalKyotoJapan

Personalised recommendations